Xu Cao

SPRY4 inhibits and sensitizes the primary KIT mutants in gastrointestinal stromal tumors (GISTs) to imatinib

Hui Zhao, R. Bai, Jianmin Sun, 2023, Gastric Cancer.

DDR1/2 enhance KIT activation and imatinib resistance of primary and secondary KIT mutants in gastrointestinal stromal tumors

Shaoting Zhang, Liangying Zhang, Sien Zhao, 2023, Molecular carcinogenesis.

Entry of ZSWIM4 to the nucleus is crucial for its inhibition of KIT and BMAL1 in gastrointestinal stromal tumors

Shaoting Zhang, Liangying Zhang, Zongying Jiang, 2024, Cell & bioscience.

Four and a half LIM domains 2 (FHL2) attenuates tumorigenesis of gastrointestinal stromal tumors (GISTs) by negatively regulating KIT signaling

Shaoting Zhang, Liangying Zhang, Zongying Jiang, 2024, Molecular carcinogenesis.

RAF1 facilitates KIT signaling and serves as a potential treatment target for gastrointestinal stromal tumor.

Shaoting Zhang, Liangying Zhang, Jun Shi, 2024, Oncogene.